Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSCINASDAQ:DWTXNASDAQ:GRAYNASDAQ:SCNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSCICOSCIENS Biopharma$3.50+4.8%$3.19$1.96▼$6.77$11.01M0.8912,329 shs696 shsDWTXDogwood Therapeutics$5.60-1.8%$4.85$1.62▼$29.28$10.70M1.981.75 million shs71,219 shsGRAYGraybug Vision$1.76-2.2%$1.78$5.00▼$22.12$2.77M1.22,165 shs11,759 shsSCNXScienture$0.93+4.5%$1.01$0.69▼$9.55$12.20M2.831.06 million shs73,162 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSCICOSCIENS Biopharma+1.19%-2.48%+8.19%+21.57%+349,999,900.00%DWTXDogwood Therapeutics-1.75%+5.07%+0.18%+18.90%+559,999,900.00%GRAYGraybug Vision-2.22%-5.38%+17.33%-23.81%-66.15%SCNXScienture+4.49%+3.33%-7.92%-65.22%+92,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ADWTXDogwood Therapeutics1.7257 of 5 stars3.50.00.00.02.70.00.6GRAYGraybug VisionN/AN/AN/AN/AN/AN/AN/AN/ASCNXScientureN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSCICOSCIENS Biopharma 0.00N/AN/AN/ADWTXDogwood Therapeutics 3.00Buy$10.0078.57% UpsideGRAYGraybug Vision 0.00N/AN/AN/ASCNXScienture 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GRAY, SCNX, CSCI, and DWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSCICOSCIENS Biopharma$9.03M1.22N/AN/A$14.99 per share0.23DWTXDogwood TherapeuticsN/AN/AN/AN/A$4.94 per shareN/AGRAYGraybug VisionN/AN/AN/AN/A$1.67 per shareN/ASCNXScienture$146.90K83.03N/AN/A$0.45 per share2.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSCICOSCIENS Biopharma-$16.55M-$5.80N/A∞N/A-428.43%-95.93%-45.66%8/11/2025 (Estimated)DWTXDogwood Therapeutics-$5.30M-$18.04N/AN/AN/AN/A-217.12%-172.06%8/14/2025 (Estimated)GRAYGraybug Vision-$35.60M-$24.23N/AN/AN/AN/A-77.61%-71.34%N/ASCNXScienture-$17.84MN/A0.00∞N/AN/A-77.60%-62.29%6/25/2025 (Estimated)Latest GRAY, SCNX, CSCI, and DWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CSCICOSCIENS BiopharmaN/A-$1.16N/A-$1.16N/A$1.50 million5/12/2025Q1 2025SCNXScientureN/A-$0.33N/A-$0.33N/A$0.01 million5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/A4/9/2025Q4 2024CSCICOSCIENS Biopharma-$3.48-$2.15+$1.33-$2.15$1.10 million$3.32 million3/31/2025Q4 2024DWTXDogwood Therapeutics-$1.49-$6.29-$4.80-$6.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCSCICOSCIENS BiopharmaN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AGRAYGraybug VisionN/AN/AN/AN/AN/ASCNXScientureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSCICOSCIENS BiopharmaN/A3.463.05DWTXDogwood TherapeuticsN/A1.711.71GRAYGraybug VisionN/A10.7310.72SCNXScienture0.031.341.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSCICOSCIENS Biopharma0.73%DWTXDogwood Therapeutics9.05%GRAYGraybug Vision49.94%SCNXScienture5.68%Insider OwnershipCompanyInsider OwnershipCSCICOSCIENS Biopharma0.10%DWTXDogwood Therapeutics3.90%GRAYGraybug Vision7.94%SCNXScienture49.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSCICOSCIENS Biopharma203.15 million3.77 millionN/ADWTXDogwood Therapeutics51.91 million1.17 millionN/AGRAYGraybug Vision271.57 million20.25 millionNot OptionableSCNXScientureN/A13.12 million4.40 millionN/AGRAY, SCNX, CSCI, and DWTX HeadlinesRecent News About These CompaniesScienture Holdings, Inc. Announces Leadership Transition as Suren Ajjarapu Steps Down as CEO and ChairmanMay 22, 2025 | quiverquant.comSCIENTURE Announces Executive Leadership TransitionMay 22, 2025 | globenewswire.comScienture Holdings, Inc. Announces FDA Patent Listing for Arbli™, First FDA-Approved Liquid Losartan FormulationMay 19, 2025 | quiverquant.comSCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.May 19, 2025 | globenewswire.comScienture Holdings: Q1 Earnings SnapshotMay 13, 2025 | timesunion.comScienture initiates supply chain activities by subsidiary to launch ArbliApril 24, 2025 | markets.businessinsider.comScienture Holdings, Inc. Announces Supply Chain Readiness for Launch of FDA-Approved ArbliTM Oral Suspension in July 2025April 22, 2025 | quiverquant.comSCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.April 22, 2025 | globenewswire.comScienture Holdings Divests Subsidiaries to Tollo HealthApril 11, 2025 | tipranks.comSCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment ...April 10, 2025 | seekingalpha.comScienture divests Integra Pharma Solutions, Bonum Health, Softell for $5MApril 10, 2025 | markets.businessinsider.comSCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.April 8, 2025 | globenewswire.comScienture files to sell 2.64M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comScienture CEO says focused on execution, growth, expansion for years aheadApril 4, 2025 | markets.businessinsider.comScienture Holdings, Inc. Issues Annual Letter to ShareholdersApril 3, 2025 | globenewswire.comSCNX Scienture Holdings, Inc.April 2, 2025 | seekingalpha.comScienture appoints Rath as CCO, enters agreement with SyneosMarch 26, 2025 | markets.businessinsider.comScienture Holdings, Inc. Appoints Michele Rath as Senior Vice President and Chief Commercial OfficerMarch 25, 2025 | quiverquant.comSCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales OrganizationMarch 25, 2025 | globenewswire.comScienture announces draaw on Equity Line of CreditMarch 20, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRAY, SCNX, CSCI, and DWTX Company DescriptionsCOSCIENS Biopharma NASDAQ:CSCI$3.51 +0.17 (+5.06%) As of 05/28/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Dogwood Therapeutics NASDAQ:DWTX$5.60 -0.10 (-1.75%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$5.52 -0.09 (-1.52%) As of 05/28/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Graybug Vision NASDAQ:GRAY$1.76 -0.04 (-2.22%) As of 05/27/2025Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.Scienture NASDAQ:SCNX$0.93 +0.04 (+4.49%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.90 -0.04 (-3.76%) As of 05/28/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
